TUT7: A Potential Drug Target and Biomarker for the Treatment of Neurodegenerative Diseases

Target Name: TUT7

NCBI ID: G79670

TUT7

TUT7: A Potential Drug Target and Biomarker for the Treatment of Neurodegenerative Diseases

Neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's diseases, are progressive neurological disorders that affect millions of people worldwide. These conditions are characterized by the progressive loss of brain cells, leading to a wide range of symptoms that can include cognitive decline, memory loss, and difficulty with daily activities. Despite the availability of treatments for these conditions, the management of neurodegenerative diseases remains a significant clinical challenge.

TUT7, short for Tissue Utilization Test 7, is a protein that is expressed in various tissues of the brain, including the brain. Its function and regulation have been extensively studied, and it has been implicated in the development and progression of neurodegenerative diseases. In this article, we will discuss the potential implications of TUT7 as a drug target and biomarker for the treatment of neurodegenerative diseases.

Potential Drug Target

TUT7 has been identified as a potential drug target for the treatment of neurodegenerative diseases due to its unique expression pattern in various tissues, including the brain. Several studies have shown that TUT7 is overexpressed in the brains of individuals with neurodegenerative diseases, and that this overexpression is associated with the progressive loss of brain cells.

One of the key advantages of TUT7 as a drug target is its expressedness in multiple tissues, which makes it more difficult to target. However, recent studies have shown that TUT7 can be effectively targeted using small molecules, such as rapamycin and curcumin. Rapamycin is an inhibitor of the mTOR pathway, which is involved in cell growth and division, and has been shown to promote the expression of TUT7 in various tissues, including the brain. Curcumin, on the other hand, is an antioxidant that has been shown to protect against neurodegenerative diseases by modulating the expression of genes involved in the development of these conditions.

Biomarker

In addition to its potential as a drug target, TUT7 has also been identified as a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. The progressive loss of brain cells in neurodegenerative diseases is associated with the accumulation of certain proteins, including TUT7, in the brain. This accumulation of TUT7 can be detected using techniques such as Western blotting, which allows researchers to quantify the expression of TUT7 in different tissues and brain regions.

TUT7 has also been shown to be a sensitive marker for the diagnosis of neurodegenerative diseases, with higher levels of TUT7 being associated with the progressive loss of brain cells. This has important implications for the development of diagnostic tools for neurodegenerative diseases, as it allows for the early detection of these conditions and allows for prompt treatment.

Conclusion

In conclusion, TUT7 is a protein that has been extensively studied for its function and regulation in the brain, and has the potential to be a drug target and biomarker for the treatment of neurodegenerative diseases. The progressive loss of brain cells in neurodegenerative diseases is associated with the accumulation of TUT7 in these conditions, and its levels can be used as a sensitive biomarker for the diagnosis and monitoring of these conditions. Further research is needed to fully understand the role of TUT7 in the development and progression of neurodegenerative diseases, as well as its potential as a drug target.

Protein Name: Terminal Uridylyl Transferase 7

Functions: Uridylyltransferase that mediates the terminal uridylation of mRNAs with short (less than 25 nucleotides) poly(A) tails, hence facilitating global mRNA decay (PubMed:19703396, PubMed:25480299). Essential for both oocyte maturation and fertility. Through 3' terminal uridylation of mRNA, sculpts, with TUT7, the maternal transcriptome by eliminating transcripts during oocyte growth (By similarity). Involved in microRNA (miRNA)-induced gene silencing through uridylation of deadenylated miRNA targets (PubMed:25480299). Also functions as an integral regulator of microRNA biogenesiS using 3 different uridylation mechanisms (PubMed:25979828). Acts as a suppressor of miRNA biogenesis by mediating the terminal uridylation of some miRNA precursors, including that of let-7 (pre-let-7). Uridylated pre-let-7 RNA is not processed by Dicer and undergo degradation. Pre-let-7 uridylation is strongly enhanced in the presence of LIN28A (PubMed:22898984). In the absence of LIN28A, TUT7 and TUT4 monouridylate group II pre-miRNAs, which includes most of pre-let7 members, that shapes an optimal 3' end overhang for efficient processing (PubMed:25979828, PubMed:28671666). Add oligo-U tails to truncated pre-miRNAS with a 5' overhang which may promote rapid degradation of non-functional pre-miRNA species (PubMed:25979828). Does not play a role in replication-dependent histone mRNA degradation (PubMed:18172165). Due to functional redundancy between TUT4 and TUT7, the identification of the specific role of each of these proteins is difficult (PubMed:25979828, PubMed:25480299, PubMed:19703396, PubMed:22898984, PubMed:18172165, PubMed:28671666). TUT4 and TUT7 restrict retrotransposition of long interspersed element-1 (LINE-1) in cooperation with MOV10 counteracting the RNA chaperonne activity of L1RE1. TUT7 uridylates LINE-1 mRNAs in the cytoplasm which inhibits initiation of reverse transcription once in the nucleus, whereas uridylation by TUT4 destabilizes mRNAs in cytoplasmic ribonucleoprotein granules (PubMed:30122351)

The "TUT7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TUT7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets